PT Kalbe Farma Tbk
PTKFF
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.03B
Close$
$0.12
178.2% upside
Current Fair Value
178.2% upsideUndervalued by 178.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.03 Billion |
|---|---|
| Enterprise Value | $-4,032,002,694,186.00 |
| Dividend Yield | $0.00 (2.78%) |
| Earnings per Share | $80.51 |
| Beta | -0.19 |
| Outstanding Shares | 45,248,860,000 |
Return
| Return on Equity | 12.09% |
|---|---|
| Return on Assets | 8.89% |
| Return on Invested Capital | 14.21% |
Valuation & Multiples
| P/E Ratio | 9.04 |
|---|---|
| PEG | -6480.22 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 0.99 |
| Enterprise Value to EBIT | 7.55 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$0.00
Average shareholder expectationRevenue Estimate
$571.02 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.00
Average shareholder expectationRevenue Estimate
$557.95 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PT Kalbe Farma Tbk
12,806 employees
CEO: Vidjongtius PT Kalbe Farma Tbk engages in the development, distribution, and trading of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. T...